Market Size of North America Diabetes Care Devices Industry
| Study Period | 2019- 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 27.52 Billion |
| Market Size (2029) | USD 37.19 Billion |
| CAGR (2024 - 2029) | 6.21 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Diabetes Care Devices Market Analysis
The North America Diabetes Care Devices Market size is estimated at USD 27.52 billion in 2024, and is expected to reach USD 37.19 billion by 2029, growing at a CAGR of 6.21% during the forecast period (2024-2029).
The PAHO Panorama of Diabetes report highlights the alarming increase in diabetes cases in the Americas. The projected number of individuals affected by diabetes is expected to rise from 62 million in 2022 to 109 million by 2040 if current patterns persist. This emphasizes the urgent need for increased awareness, prevention, and management strategies to address this growing public health challenge. Further, the report emphasizes the importance of early detection and diagnosis, as many individuals may be living with diabetes without even realizing it. This lack of awareness can delay necessary treatment and increase the risk of complications. Therefore, efforts to improve screening and testing for diabetes are crucial to identify and support those who are affected.
The North American region has witnessed an astounding increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people.
Patients with Type 2 diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be very difficult without multiple daily injections of insulin or insulin pump therapy. This is driving the demand for diabetes care devices in North America, thereby driving the market in focus during the forecast period.
